Navigation Links
Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results
Date:2/14/2008

- Second Quarter Revenue Increased 69.8% to $7.7 million

- Gross Margins Increased from 37% to 41%

- Second Quarter Net Income Increased 67.5% to $1.7 million - First Six Months Revenues Increased 82% to $14.9 million and Net Income

Increased 65% to $3.2 million for the Same Period - Growth Driven by New Distribution Partners and Increased Demand for

Products

CHENGDU, China, Feb. 14 /Xinhua-PRNewswire-FirstCall/ -- Tianyin Pharmaceutical, Inc., (OTC Bulletin Board: VSCO), a manufacturer and supplier of modernized traditional Chinese medicine (TCM) based in Chengdu, China, today announced fiscal results for its second quarter ending December 31, 2007.

Total revenue for the second quarter of 2008 increased 69.8% to approximately $7.7 million compared to approximately $4.3 million for the second quarter of 2007. Cost of goods sold for the second quarter of 2008 was approximately $4.6 million, yielding a gross profit of approximately $3.2 million and gross margins of 41%, compared to approximately $1.6 million in gross profit at a gross margin of 37.2% during the second quarter of 2007.

Operating income for the second quarter of 2008 totaled approximately $2 million, representing a 68% increase from the $1.2 million reported for the second quarter of 2007 and was directly related to the increase in revenues. Operating margins were 25.5% and 27.1% for the second quarter of 2008 and 2007, respectively.

For the second quarter of 2008, net income was approximately $1.7 million, an increase of 67.5% from $986,317 recorded during the second quarter of 2007. The Company incurred taxes of $300,000 and $160,000 for the second quarter of 2008 and 2007, respectively, which equated to an effective tax rate of 15% and 13.6%. Tianyin had 14.6 million shares outstanding on February 12, 2008.

Tianyin has experienced significant growth over the previous period due to their continuous efforts in penetrating the market. The Company signed six sizable regional distributors who facilitated the reach of Tianyin's products into previously inaccessible market regions. Tianyin increased its sales force at the district level and thus increased its coverage at drug stores, clinics, hospitals and distributors. The Company also witnessed stronger than expected demand for leading products including Qinrejiedu Oral Liquid and Ginkgo Mihuan. Television-based marketing for Arphshuangxing also contributed to the increased demand by generating additional sales in the regions where campaigns aired.

"We are very pleased with our performance for both the second quarter and year to date. 2008 has proven to be an inflection point for our Company after we entered the U.S. capital markets with a $15 million investment by a diverse group of institutional investors in support of our highly qualified and competent management team," stated Dr. Guoqing Jiang, Chief Executive Officer of Tianyin. "These results are the culmination of hard work, prudent planning and solid execution on behalf of our entire organization. The underlying growth dynamics, supported by increases in disposable income and improving fundamentals in the overall modern traditional Chinese medicine industry provide further confirmation that we are properly positioned to capitalize on this opportunity on a go forward basis."

Six Month Results

For the six months ended December 31, 2007, revenues increased approximately 82% to $14.9 million compared to the same period in 2006. Gross profit was $6.1 million for the first six months of 2008, representing an increase of 94.3% from the first six months of 2007. Gross margins were 40.6% for the first six months of 2008 compared to 38% for the same period in 2007. Income from operations was $3.8 million for the first six months of 2008, representing an increase of 65% over the first six months of 2007. Operating margins were 25.4% for the first six months of 2008 compared to 28% for the first six months of 2007. Net income was $3.2 million for the six months ended December 31, 2007, an increase of 65% from the same period in 2006.

Balance Sheet and Cash Flow

The Company had a current ratio of 2.6 to 1 and $4.6 million in cash and accounts receivable on December 31, 2007. The Company reported $1.3 million in short-term notes and no long-term debt. For the first six months of 2008, the Company provided $1.75 million in cash for operations, the main driver for cash flow was net income of $3.2 million and a significant increase in revenues. On January 28, 2008, subsequent to the end of their second quarter, Tianyin announced a private placement of $15.2 million.

"I would like to thank all of the investors who participated in our recent private placement. This capital will be used to significantly expand our production capacity during the coming six to twelve months to meet demand supported by the continued growth in expenditures per capita on Traditional Chinese Medicines (TCMs) and government support for additional cost reimbursement of our products," stated Jiang. "TCM's have been deeply ingrained in Chinese culture for thousands of years and long been perceived by many Chinese to be both safe and efficacious. Strong government support to include more TCM's to the list of medicines subject to reimbursement in the National Medicine Catalog, along with the Chinese SFDA's plan to release more product approvals will be advantageous for the future growth prospects for our large pipeline of new products."

Conference Call

The Company will host a conference call to discuss the 2008 second quarter financial results on Thursday, February 14, 2008 at 4:15 p.m. EST. Interested participants should call 800-762-8908 within the United States, or US +1-480- 629-1990 if calling internationally. It is advisable to dial in approximately 5-10 minutes prior to the 4:15 p.m. EST start time. There will be a playback available until March 15, 2008. To listen to the playback, please call 800- 406-7325 from within the United States, or US +1-303-590-3030 internationally. Please use pass code 3843464 for the replay. The call will also be Web cast at the following link: http://viavid.net/dce.aspx?sid=00004BD5

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by current management team in August 2003. It has a comprehensive product portfolio of 34 modernized TCMs in the market, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance Program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 51 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 523 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 869 employees. Tianyin achieved revenue of $20.4 million and net income of $3.95 million in FY2007 ending June 30, 2007.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

-- FINANCIAL TABLES TO FOLLOW --

PART I - FINANCIAL INFORMATION

BALANCE SHEET

AS OF DECEMBER 31, 2007

(UNAUDITED)

ASSETS

CURRENT ASSETS

Cash and cash equivalents $1,359,417

Accounts receivable, net of allowance of $32,860 3,260,179

Inventory 1,632,624

Advance payment to vendors 1,068,009

Other receivables 781,751

Total Current Assets 8,101,980

PROPERTY AND EQUIPMENT, NET 4,729,442

INTANGIBLES, NET 6,056,407

Total Assets $18,887,829

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES

Accounts payable and accrued expenses $991,250

Short-term bank loans 1,309,305

Due to shareholders 145,517

VAT taxes payable 202,313

Income tax payable 296,912

Payroll taxes payable

22,254

Other payables 194,998

Total Current Liabilities 3,162,549

STOCKHOLDERS' EQUITY

Capital contribution 363,000

Additional paid-in capital 4,347,508

Statutory reserve 683,437

Retained earnings 9,323,261

Accumulated other comprehensive income 1,008,074

Total Stockholders' Equity 15,725,280

Total Liabilities and Stockholders' Equity $18,887,829

STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

(UNAUDITED)

Six Months Ended Three Months Ended

December 31, December 31,

2007 2006 2007 2006

SALES $14,918,692 $8,210,022 $7,749,199 $4,344,846

COST OF GOODS SOLD 8,861,258 5,091,764 4,567,429 2,702,593

GROSS PROFIT 6,057,434 3,118,258 3,181,770 1,642,253

EXPENSES

Selling, general and

administrative 2,200,541 801,776 1,172,062 457,519

Research and

development 61,558 13,380 34,106 6,269

Total Expenses 2,262,099 815,156 1,206,168 463,788

INCOME FROM OPERATIONS 3,795,335 2,303,102 1,975,602 1,178,466

OTHER INCOME (EXPENSES)

Other income -- 1,432 --

Interest expense (66,362) (71,745) (31,659) (36,604)

Total Other Income

(Expenses) (66,362) (70,313) (31,659) (36,604)

INCOME BEFORE PROVISION FOR

INCOME TAX 3,728,973 2,232,789 1,943,943 1,141,862

PROVISION FOR INCOME TAX 556,646 310,936 291,572 155,545

NET INCOME 3,172,327 1,921,853 1,652,371 986,317

OTHER COMPREHENSIVE INCOME

Foreign currency

translation adjustment 574,966 106,623 391,115 62,937

COMPREHENSIVE INCOME $3,747,293 $2,028,476 $2,043,486 $1,049,254

STATEMENTS OF CASH FLOWS

FOR THE SIX MONTHS ENDED DECEMBER 31,

(UNAUDITED)

2007 2006

CASH FLOWS FROM OPERATING ACTIVITIES

Net Income $3,172,327 $1,921,853

Adjustments to reconcile net income to net

cash

provided by operating activities:

Depreciation and amortization 164,758 221,171

Bad debt expense -- 19,308

Changes in current assets and current

liabilities:

Accounts receivable

(6,899) (1,392,038)

Inventory 306,194 (400,339)

Advance payments to vendors (1,040,484) 462,864

Other receivables

(624,610) 22,354

Accounts payable and accrued

expenses (252,002) 355,753

VAT taxes payable

(16,051) 19,584

Income tax payable

(20,953) (683)

Payroll taxes payable

(1,707) (13,584)

Other payables

66,426 (174,200)

Total Adjustments (1,425,328) (879,810)

Net Cash Provided by Operating

Activities 1,746,999 1,042,043

CASH FLOWS FROM INVESTING ACTIVITIES

Acquisition of property and equipment (133,591) (50,719)

Additions to intangibles

-- (860,200)

Net Cash Used by Investing

Activities (133,591) (910,919)

CASH FLOWS FROM FINANCING ACTIVITIES

Repayment of short-term bank loans (801,540) --

Repayment of shareholder loans -- (13)

Repayment of long-term bank loans

(121,569) (40,123)

Net Cash Used by Financing

Activities (923,109) (40,136)

EFFECT OF FOREIGN CURRENCY TRANSLATION ON 44,728 18,970

CASH

NET INCREASE IN CASH AND CASH EQUIVALENTS 735,027 109,958

CASH AND CASH EQUIVALENTS - BEGINNING 624,390 740,780

CASH AND CASH EQUIVALENTS - ENDING $1,359,417 $850,738


'/>"/>
SOURCE Tianyin Pharmaceutical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... WARRINGTON, Pa. , Feb. 3, 2016 /PRNewswire/ ... biotechnology company focused on developing aerosolized KL4 surfactant ... Board of Directors has approved an inducement award ... Craig Fraser , its newly appointed President and ... the Board,s Compensation Committee on February 1, 2016 ...
(Date:2/3/2016)... 2016 Ascendis Pharma A/S (Nasdaq: ASND ... innovative TransCon technology to address significant unmet medical needs, ... conference.Event:2016 Leerink Partners Global Healthcare Conference Location: , ... 10, 2016 Time:  , 11:55am EST ... An audio webcast of this event will be ...
(Date:2/3/2016)... 3, 2016 New Jersey Health Foundation (NJHF) ... million for researchers in New Jersey ... that demonstrates exciting potential.   James ... the New Jersey Health Foundation Research Grant Program ... educational institutions— Princeton University, Rutgers University, Rowan University ...
(Date:2/3/2016)... ... February 03, 2016 , ... ProMIS Neurosciences ... targets (epitopes) specific to misfolded, propagating strains of Amyloid beta involved in Alzheimer’s ... therapeutics for Alzheimer’s. , Following on from the first misfolded Amyloid beta target ...
Breaking Biology Technology:
(Date:2/1/2016)... -- Wocket® smart wallet ( www.wocketwallet.com ) announces the launch of a new ... Las Vegas , where Joey appeared at the ... Las Vegas , where Joey appeared at the Wocket booth to ... was filmed at the Consumer Electronics Show (CES2016) in Las ... and greet fans. --> --> ...
(Date:1/22/2016)... January 22, 2016 ... addition of the  "Global Behavioral Biometric ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ... Behavioral Biometric Market 2016-2020"  report to ... and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ...
(Date:1/20/2016)... 20, 2016  Synaptics Incorporated (NASDAQ: SYNA ... today announced sampling of S1423, its newest ClearPad ... small screen applications including smartwatches, fitness trackers, and ... and rectangular shapes, as well as thick and ... moisture on screen, while wearing gloves, and supports ...
Breaking Biology News(10 mins):